EcoDrugPlus

Glutamate Receptor 4

Ensembl ID : ENSCSEG00000015575
Gene Symbol: LOC103395367
3 Cross references
252 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 1

Ensembl ID : ENSCSEG00000001410
Gene Symbol: LOC103389281
3 Cross references
203 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2b-Like

Ensembl ID : ENSCSEG00000006690
Gene Symbol: LOC103383797
3 Cross references
256 Possible Orthologues:

Glutamate Receptor Ionotropic, Kainate 1-Like

Ensembl ID : ENSCSEG00000019453
Gene Symbol: LOC103395511
2 Cross references
246 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 2a

Ensembl ID : ENSCSEG00000015384
Gene Symbol: GRIA2A
1 Cross references
244 Possible Orthologues:

Glutamate Receptor, Metabotropic 5b

Ensembl ID : ENSCSEG00000018704
Gene Symbol: GRM5B
1 Cross references
217 Possible Orthologues:

Glutaminase Kidney Isoform, Mitochondrial-Like

Ensembl ID : ENSCSEG00000005440
Gene Symbol: LOC103389519
3 Cross references
236 Possible Orthologues:

Glutaminase Kidney Isoform, Mitochondrial-Like

Ensembl ID : ENSCSEG00000016444
Gene Symbol: LOC103392402
2 Cross references
225 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSCSEG00000011412
Gene Symbol: GSK3B
3 Cross references
208 Possible Orthologues:

Glycogen Synthase Kinase-3 Beta

Ensembl ID : ENSCSEG00000019516
Gene Symbol: LOC103387999
3 Cross references
187 Possible Orthologues:

Glycogen Synthase Kinase-3 Beta-Like

Ensembl ID : ENSCSEG00000020334
Gene Symbol: LOC103393872
2 Cross references
164 Possible Orthologues:

Gonadotropin-Releasing Hormone Ii Receptor-Like

Ensembl ID : ENSCSEG00000015396
Gene Symbol: LOC103394313
3 Cross references
174 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).